ATTRACT is a Research Study for an Oral Investigational Treatment for Fabry Disease

The ATTRACT Study is evaluating the safety and effectiveness of an investigational, orally administered pharmacological chaperone for the treatment of Fabry disease.

The ATTRACT Study is a Phase 3 clinical trial that will measure the effectiveness and safety of an investigational pharmacological chaperone migalastat HCl (AT1001 or GR181413A), when compared to enzyme replacement therapy (ERT) agalsidase, for the treatment of patients with Fabry disease.

The study is open to men and women between the ages of 16 and 74 years who have been diagnosed with Fabry disease. Individuals may be eligible if they have been receiving agalsidase (ERT) for the last 12 months and have been on a stable dose and regimen for the 3 months prior to the study treatment period.

The ATTRACT study is being conducted at sites in countries around the world, including sites in Europe, the United States, Australia, Japan, South America, Taiwan, and the Middle East. In the United States, the study will be conducted in various states from coast-to-coast. Additional locations are continually being added. Check website or contact us for more details.